Global strategic partners bioeq and Formycon initiate pivotal phase III clinical trial with their Lucentis® biosimilar

(PresseBox) ( Munich, )

Formycon and Bioeq initiate pivotal Phase III clinical trial for FYB201, an investigational biosimilar ranibizumab (Lucentis®)*
Global program underscores Formycon’s and bioeq’s leadership in ophthalmology biosimilars
Both companies continue to advance biosimilar pipeline  

Formycon AG, Munich, Germany, and bioeq GmbH, Holzkirchen, Germany, today announced the initiation of a pivotal Phase III clinical trial with FYB201, an investigational biosimilar ranibizumab (Lucentis®). The global clinical trial is designed to confirm biosimilarity with regard to safety, efficacy and immunogenicity of FYB201 versus Lucentis® in patients with neovascular age-related macular degeneration (nAMD). The study design was developed in consultation with the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) and is expected to support the registration in both regions.

Top selling eye drug Lucentis® is the leading treatment for nAMD and other eye diseases and had estimated sales of $4.1 billion in 2014. It inhibits vascular endothelial growth factor (VEGF) which is responsible for the excessive formation of blood vessels in the retina leading to progressive loss of vision. The current total market size for intraocular anti-VEGF therapy is about $6.9 billion.

Formycon had licensed FYB201 exclusively to Santo Holding GmbH, Holzkirchen, Germany end of 2013. bioeq GmbH, an affiliate of Santo Holding GmbH, acts as the sponsor of the Phase III study and will also be responsible for the global commercialization and licensing of FYB201.

Carsten Brockmeyer, Ph.D., CEO Formycon AG: “We believe that we are the first company initiating a pivotal phase III study for a biosimilar version of ranibizumab. This underlines our mission to provide high quality biologics to patients across the world. I am glad that Formycon and bioeq will jointly drive the clinical development, regulatory filings and commercialization of FYB201, which will help us to become a significant player in the field of ophthalmological diseases, one of the most rapidly growing therapeutic areas. We continue to advance our pipeline with two other biosimilar candidates already in preclinical phase.”

“Intraocular anti-VEGF agents are a cornerstone in the treatment of age related macular degeneration and other eye diseases. A high quality and clinically proven biosimilar version of Lucentis® could play an important role in broadening the access to these essential medicines and generating much needed savings” said Professor Dr. O. Findl, Chair of the Department of Ophthalmology at Hanusch Hospital, Vienna.

“The costs associated with the treatment of eye diseases have become a tremendous emerging challenge for global health care systems. I am confident that, together with our partner Formycon, we can build a strong global presence in ophthalmology. Biosimilars like FYB201 will address the need for affordable access to essential high-quality treatments for payors, prescribers and patients. We continue to expand our biosimilar portfolio in ophthalmology but also in other indications” said Nicola Mikulcik, CEO of bioeq GmbH.

* Lucentis is a registered trademark of Genentech Inc

Background: What are biosimilars?
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis and multiple sclerosis. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of more than USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the Biosimilar with the originator biopharmaceutical reference product. While the global market for biosimilars is currently some USD 2.5 billion, industry experts expect this figure to grow tenfold by the year 2020. In contrast to traditional generic drugs, the development and production of biosimilars is highly complex and requires specialized expertise.

About bioeq GmbH
bioeq GmbH was established in May 2014 and is funded by the Strüngmann Group (Santo Holding) and by Polpharma, a leading Polish pharmaceutical company. bioeq is active in the development of biosimilars in compliance with standards required for approval and distribution in the EU, US and other highly regulated markets. Starting from early stage development projects licensed from internationally renowned partners or cell lines stemming from affiliated companies, bioeq conducts development programs up to clinical development and registration. bioeq’s pipeline comprises several of the so-called “third wave” biosimilars, for which patent protection is due to expire within the next decade. Bioeq’s management team combines expert scientists and senior management with a skill set spanning from early stage development through to commercialization of complex molecules and biosimilars.

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to variety of risks and uncertainties. The results actually achieved by Formycon AG may substantially differ from these forward-looking statements. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. 
This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an